The most recent trading session ended with AbbVie (ABBV - Free Report) standing at $180.76, reflecting a -0.74% shift from the previouse trading day's closing. This move lagged the S&P 500's daily loss of 0.2%. At the same time, the Dow lost 0.6%, and the tech-heavy Nasdaq gained 0.11%.
The drugmaker's shares have seen an increase of 1.78% over the last month, not keeping up with the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32%.
Analysts and investors alike will be keeping a close eye on the performance of AbbVie in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $2.34, reflecting a 4.88% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.94 billion, down 2.31% from the year-ago period.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $11.16 per share and revenue of $54.5 billion. These results would represent year-over-year changes of +0.45% and +0.33%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for AbbVie. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.05% upward. AbbVie currently has a Zacks Rank of #3 (Hold).
Investors should also note AbbVie's current valuation metrics, including its Forward P/E ratio of 16.31. This indicates a premium in contrast to its industry's Forward P/E of 14.85.
It's also important to note that ABBV currently trades at a PEG ratio of 2.31. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.76 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 211, finds itself in the bottom 17% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
The most recent trading session ended with AbbVie (ABBV - Free Report) standing at $180.76, reflecting a -0.74% shift from the previouse trading day's closing. This move lagged the S&P 500's daily loss of 0.2%. At the same time, the Dow lost 0.6%, and the tech-heavy Nasdaq gained 0.11%.
The drugmaker's shares have seen an increase of 1.78% over the last month, not keeping up with the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32%.
Analysts and investors alike will be keeping a close eye on the performance of AbbVie in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $2.34, reflecting a 4.88% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.94 billion, down 2.31% from the year-ago period.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $11.16 per share and revenue of $54.5 billion. These results would represent year-over-year changes of +0.45% and +0.33%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for AbbVie. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.05% upward. AbbVie currently has a Zacks Rank of #3 (Hold).
Investors should also note AbbVie's current valuation metrics, including its Forward P/E ratio of 16.31. This indicates a premium in contrast to its industry's Forward P/E of 14.85.
It's also important to note that ABBV currently trades at a PEG ratio of 2.31. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.76 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 211, finds itself in the bottom 17% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Get the latest research report on ABBV - FREE